Morning Breakouts

Latest California Healthline Stories

Kaiser Permanente Reports 90% Increase in 2002 First-Quarter Net Income

Oakland-based Kaiser Permanente, the nation’s largest not-for-profit HMO, yesterday reported a 90% increase in net income in the first quarter of 2002 as a result of “cost-cutting and higher premiums,” the San Francisco Chronicle reports.

Daschle Says Mental Health Parity Legislation Will Reach Senate Floor By Memorial Day

In response to President Bush’s call for Congress to approve mental health parity legislation, Senate Majority Leader Tom Daschle (D-S.D.) yesterday said that such legislation will reach the Senate floor “in the coming months,” perhaps before Memorial Day, CongressDaily/AM reports.

Competing Medicare Prescription Drug Benefit Bills to Be Announced Today

House Speaker Dennis Hastert (R-Ill.) today is expected to announce the details of GOP-backed Medicare prescription drug legislation that would use private companies to provide coverage and would include President Bush’s proposal for government-issued prescription drug discount cards, the AP/Boston Globe reports.

One in Ten Prescription Drugs Either Pulled from Market, Get Label Warning After FDA Approval, Study Finds

More than 10% of prescription drugs approved by the FDA between 1975 and 1999 were either withdrawn from the market or required a label change to warn against dangerous adverse reactions, according to a study in today’s Journal of the American Medical Association.

Feinstein, Kennedy Offer Legislation Allowing Therapeutic Cloning

Sens. Dianne Feinstein (D-Calif.) and Edward Kennedy (D-Mass.) yesterday introduced legislation that would ban reproductive cloning but allow cloning for medical research purposes, and influential antiabortion lawmaker Sen. Orrin Hatch (R-Utah) announced his decision to support the measure, the Washington Post reports.

Wall Street Journal Examines ‘Precision-Targeted’ Marketing of Prescription Drugs

In a front-page story today, the Wall Street Journal examines how large drug makers pay pharmacy chains to call or send letters to customers urging them to order refills or switch to a newer version of a brand-name drug — a practice that has drawn numerous lawsuits and the attention of regulators.